Announcement from the annual general meeting in Xbrane Biopharma AB
The 2026 Annual General Meeting of Xbrane Biopharma AB adopted the company’s income statement and balance sheet.

Xbrane Biopharma develops biological drugs on a patented platform with significantly lower production costs than competing systems.
xbrane.comCrawled Nov 15, 2026
The 2026 Annual General Meeting of Xbrane Biopharma AB adopted the company’s income statement and balance sheet.
Xbrane Biopharma AB and Intas Pharmaceuticals Ltd. revised financing terms for Xbrane’s development activities related to Xdivane, a biosimilar candidate referencing Opdivo.
The U.S. Food and Drug Administration has accepted Xbrane Biopharma AB’s resubmitted Biologics License Application for its biosimilar candidate to LUCENTIS, with an action date set for October 29, 2026.
Xbrane Biopharma AB and JOINN Biologics US Inc. have formed a strategic partnership for customized development services for Xbrane’s biosimilar candidate Xdarzane.
Xbrane Biopharma AB’s nomination committee, adopted at the 2025 Annual General Meeting, consists of three members appointed by the company’s three largest shareholders.
Xbrane Biopharma AB’s nomination committee, adopted at the 2022 Annual General Meeting, includes four members, with three nominated by the company’s three largest shareholders based on voting power.
Xbrane Biopharma publishes its interim financial and operational report covering the first nine months of 2026. The document is made available on the company’s official website for investor and stakeholder review.
Xbrane receives FDA approval for **Lucamzi™**, a biosimilar to **Lucentis® (ranibizumab)**. The company plans to prepare for the product’s launch in **2027** in collaboration with partners. Lucamzi™ targets the same retinal disease treatments as the reference drug.
Xbrane Biopharma will present its interim report covering January–September 2026 in a teleconference for investors, analysts, and media on **October 30, 2026, at 09:00 CET**. The company releases the report itself at **08:00 CET** the same day. The event provides an update on the biopharma’s performance and operational progress.
Xbrane Biopharma completes enrollment for its pivotal clinical trial of **Xdivane**, a biosimilar to **Opdivo (nivolumab)**. The trial now includes all planned participants, marking a key milestone in the development of the company’s first biosimilar candidate. Xbrane specializes in biosimilar therapies and aims to expand access to oncology treatments through its pipeline.
Xbrane Biopharma’s nomination committee, appointed for the period until a new committee is designated, consists of three members selected by the company’s three largest shareholders by voting power as of September 30, 2026. The Chairman of the Board serves as an adjunct member when required. The committee operates under principles adopted at the Annual General Meeting on May 5, 2026.